We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Supercomputer Simulates Beating Heart, Helping Drive Research

By LabMedica International staff writers
Posted on 04 Dec 2012
A new supercomputer had been built specifically to tackle weapon simulations, but before it goes into its intended work, it is generating cutting-edge cardiac simulations.

The Sequoia [IBM’s BlueGene/Q] holds the number two rank in the November 2012 TOP500 list of the world’s fastest computer systems [top ranked in the June 2012 TOP500 list]. More...


Sequoia is bringing modeling and simulation and modeling to new peaks, timing in at 16.32 sustained petaflops (20 PF peak), enabling scientists to capture greater complexity in a shorter period. With this advanced capability, Lawrence Livermore US National Laboratory’s (LLNL; Livermore, CA, USA) scientists have been able to simulate the human heart down to the cellular level and use the resulting model to predict how the organ will respond to different drug compounds.

The simulations were made possible by an advanced modeling program, called Cardioid, which was designed by a group of scientists from LLNL and the IBM T. J. Watson Research Center (Yorktown Heights, NY, USA). The extremely scalable code simulates the electrophysiology of the heart. It functions by breaking down the heart into units: the smaller the unit, the more effective the model. Up to now, the optimal modeling programs could attain 0.2 mm in each direction. Cardioid can jump down to 0.1 mm. Where earlier, researchers could run the simulations for tens of heartbeats, Cardioid executing on Sequoia captures thousands of heartbeats.

Scientists are experiencing 300-fold speedups. It used to take 45 minutes to simulate just one beat, but now researchers can simulate an hour of heart activity--several thousand heartbeats--in seven hours. With the less sophisticated codes, it was impossible to model the heart’s response to a drug or perform an electrocardiogram trace for a particular heart disorder. That sort of testing entails longer run times, which was not possible before Cardioid.

The model could hypothetically evaluate a range of medications and devices such as pacemakers to examine their effect on the heart, creating an avenue for more effective and safer human testing. But it is particularly suited to examining arrhythmia, a disorder of the heart in which the organ does not pump blood efficiently. Arrhythmias can lead to congestive heart failure, an inability of the heart to supply sufficient blood flow to meet the needs of the body.

There are various types of medications that disrupt cardiac rhythms. Even those designed to prevent arrhythmias can be detrimental to some patients, and researchers do not yet completely understand precisely what causes these negative side effects. Cardioid will enable LLNL scientists to examine heart function as an antiarrhythmia drug enters the bloodstream. They will be able to identify when drug levels are highest and when they decline. “Observing the full range of effects produced by a particular drug takes many hours,” noted computational scientist Art Mirin of LLNL. “With Cardioid, heart simulations over this timeframe are now possible for the first time.”

The Livermore-IBM group is also working on a mechanical model that simulates the contraction of the heart and pumping of blood. The mechanical and electrical simulations will be allowed to interact with each other, adding more realism to the heart model.

The cardiac modeling research was performed during the system’s “shakedown period”--the set-up and assessment stage--and the scientists had to rush to complete in the allotted time span. Once Sequoia becomes classified, it is uncertain if it will still be available to run Cardioid and other unclassified programs, although access will certainly be more difficult since the computer’s key mission is running nuclear weapons codes.

Sequoia is an integral part of the US National Nuclear Security Administration’s (NNSA) Advanced Simulation and Computing (ASC) program, which is run by partner organizations LLNL, Los Alamos US National Laboratory, and Sandia National Laboratories. With 96 racks, 98,304 compute nodes, 1.6 million cores, and 1.6 petabytes of memory, Sequoia will help the NNSA fulfill its mission to “maintain and enhance the safety, security, reliability, and performance of the US nuclear weapons stockpile without nuclear testing.”

The Cardioid simulation has been chosen as a finalist in the 2012 Gordon Bell Prize competition, awarded each year to recognize supercomputing’s ultimate achievements. The scientists divulged their findings at the Supercomputing Conference in Salt Lake City (UT, USA), on November 13, 2012.

Related Links:

Lawrence Livermore U.S. National Laboratory
IBM T. J. Watson Research Center
US National Nuclear Security Administration




Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.